Other cancer drugs can lead to pulmonary fibrosis, like bleomycin, taxanes, and biological agents like epidermal growth factor receptor (EGFR) small-molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies to VEGF, and mammalian target of rapamycin (mTOR) inhibitors [11]. This evidence concerns the gene MTOR and pulmonary fibrosis.